Study of dienogest for dysmenorrhea and pelvic pain associated with endometriosis

Soo Ah Kim, Mi Jung Um, Han Kyoung Kim, Suk Jin Kim, Seo Ju Moon, Hyuk Jung
Obstetrics & gynecology science · 2016 · vol. 59(6) , pp. 506 · doi:10.5468/ogs.2016.59.6.506 · PMID:27896253 · PMC5120070 · W2556918156
article OA: gold CC0 ⤵ 21 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This study found that orally administered dienogest effectively reduced dysmenorrhea and pelvic pain in endometriosis patients but noted potential side effects of weight gain and uterine bleeding.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

This non-randomized prospective study evaluated oral dienogest (2 mg/day) over 6 cycles in 89 reproductive-age women with laparoscopically diagnosed endometriosis who continued to report persistent dysmenorrhea and non-menstrual pelvic pain after surgery. Using a 0–3 verbal rating scale, the authors found that dysmenorrhea disability scores, non-menstrual pelvic pain scores, and analgesic use all significantly decreased by the end of treatment, alongside no clinically relevant changes in serum lipids or liver enzymes. Reported adverse effects included weight gain (63%), irregular uterine bleeding (31.5%, with only 1 discontinuation), and no serious drug-related events otherwise. The paper’s main limitation is its single-arm design without a control comparator. This paper is centrally about endometriosis — it tests whether dienogest reduces endometriosis-associated dysmenorrhea and pelvic pain.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

OBJECTIVE: To evaluate the effect of orally administered dienogest (DNG) for dysmenorrhea and pelvic pain associated with endometriosis. METHODS: For this study we recruited 89 patients with dysmenorrhea and pelvic pain associated with endometriosis diagnosed by laparoscopy. All patients complained of persistent dysmenorrhea and pelvic pain despite surgical treatment 6 months previously. After 6 months of DNG treatment, we used a 0 to 3 point verbal rating scale to measure the severity of disability in daily life due to dysmenorrhea and pelvic pain, and the use of analgesics. Weight gain, serum lipid and liver enzyme tests were performed before treatment and after 6 months of DNG treatment. RESULTS: <0.040). CONCLUSION: This study demonstrated that orally administered DNG could be used to effectively treat dysmenorrhea and pelvic pain associated with endometriosis although the side effects of weight gain and uterine bleeding should be considered.

My notes (saved in your browser only)

Condition tags

endometriosisdysmenorrhea

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (20)

Cited by (21)

Source provenance

europepmc
last seen: 2026-06-12T06:13:51.797165+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:20:43.714878+00:00
License: CC0 · commercial use OK